Pediculosis Clinical Trial
Official title:
A Randomised, Controlled and Blinded Assessment Study of the Efficacy of MOOV Head Lice Treatment (Ego Pharmaceutical Pty. Ltd.) in the Treatment of Head Lice in Primary School Children.
Verified date | December 2006 |
Source | Uniquest Pty Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | Australia: Human Research Ethics Committee |
Study type | Interventional |
Objective
To compare the cure rates (defined as the complete absence of live lice, adults or nymphs,
as diagnosed by wet-combing of three Australian approved head lice products for the
treatment of primary school children with head lice infestation. The study design will be
randomised and assessor-blind using three comparative parallel treatment groups.
The study population will consist of Queensland state primary school children (up to Year 7)
with live head lice (adults or nymphs) on the hair or scalp who have not used any head lice
product in the four weeks prior to the study.
Status | Completed |
Enrollment | 152 |
Est. completion date | November 2004 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 5 Years to 12 Years |
Eligibility |
Inclusion Criteria: - Male or female primary school children. - Presence of live head lice (adults or nymphs) on the hair or scalp. The presence of live lice will be determined from a visual inspection of the hair and scalp and Dry-combing of the hair. Combing will stop immediately once live lice are observed. The presence of lice eggs alone is not a sufficient condition for inclusion in the trial. - Be available for the duration of the trial. - Parent / Guardian is willing not to use other head lice products or methods (e.g. combs) to treat their child’s head lice for 21 days after the first treatment. - Parent / Guardian has given written informed consent to their child’s participation in the trial. Exclusion Criteria: - History of allergies or adverse reactions to head lice products or the components of the specific products being tested. - Treatment with any head lice product in the month prior to Day 0. - Presence of scalp disease(s). - If a subject has a sibling in Grade 1-7 this sibling must also be enrolled in the study and treated on Day 0 otherwise the subject must be considered ineligible for enrolment. - Subjects must have one fixed place of residence |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | University of Queensland | Brisbane | Queensland |
Lead Sponsor | Collaborator |
---|---|
Uniquest Pty Ltd | Ego Pharmaceuticals |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Absence of live head lice one week after the last treatment for each product (ie at Day 14 for KP24 and Banlice and at Day 21 for MOOV Head Lice Treatment) | |||
Secondary | Absence of live head lice one day after the first treatment of each product |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01660321 -
Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation
|
Phase 4 | |
Completed |
NCT00752973 -
Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
|
Phase 2/Phase 3 | |
Completed |
NCT00545753 -
Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
|
Phase 3 | |
Terminated |
NCT02499549 -
Two Treatment Regimens of Cocamide DEA Lotion for Head Lice
|
Phase 2/Phase 3 | |
Completed |
NCT05643820 -
Comparison of Oral Ivermectin and Permethrin 5% Lotion in Treatment of Pediculosis Capitis
|
Phase 1 | |
Completed |
NCT00731718 -
Control of Head Lice Infestations in Children and Adults
|
N/A | |
Not yet recruiting |
NCT01966965 -
Efficacy and Safety Study for PIOLIN® Shampoo
|
Phase 3 | |
Completed |
NCT00927407 -
Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice
|
Phase 1 | |
Completed |
NCT01518699 -
Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00207753 -
Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections
|
N/A | |
Completed |
NCT00963508 -
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
|
Phase 3 | |
Completed |
NCT00927472 -
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
|
Phase 3 | |
Completed |
NCT01336647 -
An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation
|
Phase 2 |